EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

IGHV mutational status and BCR stereotypy in chronic lymphocytic leukemia: A Turkish cohort analysis

Seher Yüksel, Rahmi Şinasi Aygün, Merve Yüksel, Mehmet Berk Örüncü, Ezgi Dicle Serbes, Güldane Cengiz Seval, Önder Arslan, Muhit Özcan, Işınsu Kuzu

Annals of Hematology · 03.06.2026 · 105 (8)

DOI: 10.1007/s00277-026-07096-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 03.06.2026. Verfasst von Seher Yüksel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Medicine, Ankara University, Ankara, Türkiye. dr.sy@hotmail.com. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Mutation, Immunoglobulin Heavy Chains, Immunoglobulin Variable Region. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ankara University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunoglobulin heavy chain variable region (IGHV) mutational status and B-cell receptor (BCR) stereotypy are established prognostic markers in chronic lymphocytic leukemia (CLL). However, immunogenetic data from Türkiye and surrounding regions are scarce. We evaluated IGHV mutational status, BCR stereotypy including nearest subset assignment, and their clinical and cytogenetic correlates in a real-world Turkish CLL cohort. We retrospectively analyzed 145 patients with CLL at a tertiary referral center in Türkiye. IGHV mutational status was determined by next-generation sequencing (98% germline homology cutoff). BCR stereotypy was assigned using ARResT/AssignSubsets. Cytogenetic abnormalities were assessed by fluorescence in situ hybridization (FISH). Time-to-first treatment (TTFT), progression-free survival (PFS), and overall survival (OS) were analyzed by Kaplan–Meier method, with multivariate Cox regression for TTFT. Unmutated IGHV was detected in 55.2% of patients, higher than Western reports but consistent with Mediterranean and Middle Eastern cohorts. Unmutated cases showed adverse cytogenetics—del(11q) and multiple concurrent FISH abnormalities—whereas del(13q) predominated in mutated cases. At a median follow-up of 43.0 months unmutated status strongly predicted a profoundly shorter median TTFT compared to mutated cases (17.0 vs. 70.0 months; p < 0.0001). Notably, while an unmutated IGHV status strongly predicted a significantly shorter TTFT, it did not translate into worse PFS or OS compared to mutated cases, reflecting the transformative real-world impact and rescue capacity of modern targeted therapies utilized upon disease progression. Major stereotyped subsets were present in 15.9% of patients; subset #2 was absent, while subset #1 was predominant (39.1%). Subsets #1 and #64B were overrepresented among relapsed cases. Nearest subset #77 showed rapid progression despite mutated IGHV. CLL in Türkiye demonstrates region-specific immunogenetic features while preserving established clinico-biological correlations. Integration of IGHV status, cytogenetics, and BCR stereotypy may improve risk stratification in underrepresented populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellMutationImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionReceptors, Antigen, B-CellHumansTurkeyFemaleMaleRetrospective StudiesAgedMiddle AgedCohort StudiesAged, 80 and overIn Situ Hybridization, FluorescenceAdult

Stichwörter der Autor:innen

BCR stereotypyChronic lymphocytic leukemiaIGHV mutational statusMajor stereotyped subsetsReal-world cohort

Substanzen

Immunoglobulin Heavy ChainsImmunoglobulin Variable RegionReceptors, Antigen, B-Cell

Autor:innen und Institutionen

  • Department of Pathology, School of Medicine, Ankara University, Ankara, Türkiye. dr.sy@hotmail.com.
  • Department of Pathology, School of Medicine, Ankara University, Ankara, Türkiye.
  • Biotechnology Institute, Ankara University, Ankara, Türkiye.
  • Department of Hematology, School of Medicine, Ankara University, Ankara, Türkiye.
  • Department of Oncology, School of Medicine, Ankara University, Ankara, Türkiye.

Förderung

  • Ankara University

Zitieren

APA

Yüksel, S., Aygün, R. Ş., Yüksel, M., Örüncü, M. B., Serbes, E. D., Cengiz Seval, G., Arslan, Ö., Özcan, M., & Kuzu, I. (2026). IGHV mutational status and BCR stereotypy in chronic lymphocytic leukemia: A Turkish cohort analysis. Annals of Hematology, 105(8). https://doi.org/10.1007/s00277-026-07096-9

Vancouver

Yüksel S, Aygün RŞ, Yüksel M, Örüncü MB, Serbes ED, Cengiz Seval G, et al. IGHV mutational status and BCR stereotypy in chronic lymphocytic leukemia: A Turkish cohort analysis. Annals of Hematology. 2026;105(8). doi:10.1007/s00277-026-07096-9

BibTeX
@article{Yksel2026,
  author = {Yüksel, Seher and Aygün, Rahmi Şinasi and Yüksel, Merve and Örüncü, Mehmet Berk and Serbes, Ezgi Dicle and Cengiz Seval, Güldane and Arslan, Önder and Özcan, Muhit and Kuzu, Işınsu},
  title = {IGHV mutational status and BCR stereotypy in chronic lymphocytic leukemia: A Turkish cohort analysis},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {8},
  doi = {10.1007/s00277-026-07096-9}
}
Kostenlos starten →